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Abstract
Background: Inhaled tobramycin therapy has been shown to be efﬁcacious in clinical trials for the eradication of initial Pseudomonas aeruginosa
infection in children with cystic ﬁbrosis (CF). However, the effectiveness of different regimens in eradicating P. aeruginosa and preventing the
development of chronic infection in actual clinical settings has yet to be determined.
Methods: This was an observational study of children (b18 years of age) with CF with incident P. aeruginosa infection from 2005–2012 based on
data collected from the Toronto CF Database and medical charts. Patients who received inhaled tobramycin (80 mg/2 ml twice daily for 365 days)
were compared to those who received tobramycin inhalation solution (TIS) (300 mg/5 ml twice daily for 28 days) with respect to eradication and
development of chronic infection. We also examined the risk factors for recurrence of infection.
Results: During the study period, 65 patients were identiﬁed with incident P. aeruginosa, of which 7 (11%) failed eradication therapy. Eradication
failure was similar between the two treatment groups. A total of 4 patients (6%) developed chronic P. aeruginosa infection in the 12 months
following the end of therapy with no differences between treatment groups. Female gender, older age, pancreatic insufﬁciency, lower lung function
and worse nutritional status were identiﬁed as risk factors for recurrence of P. aeruginosa infection.
Conclusions: Both regimens of inhaled tobramycin have similar effectiveness in eradicating P. aeruginosa and preventing chronic P. aeruginosa
infection in CF patients in clinical practice. Further work is needed, however, to identify patient characteristics and bacterial factors that play a role
in eradication failure, in order to develop more effective antimicrobial rescue treatment strategies.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Children with cystic fibrosis (CF) typically develop pulmonary
infection with Pseudomonas aeruginosa early in life and without
treatment go on to develop chronic infection, typically within a
year of the first infection [1,2]. Chronic pulmonary infection with
mucoid P. aeruginosa is associated with accelerated decline in
lung function and earlier mortality in CF [3–5]. As a result, much
effort has been made to prevent the development of chronic
P. aeruginosa through various antibiotic regimens [6]. Since the
early 1980s, eradication programs for P. aeruginosa have been
attempted in younger patients with CF, with the goals to eliminate
the organism, prevent the establishment of persistent infection
and prolong the time to subsequent infection [7,8]. In addition,
although the risk factors for initial P. aeruginosa infection have
been defined, factors affecting the risk of re-infection have yet to
be determined [9–11]. Failure to eradicate P. aeruginosa has been
shown to be associated with an increased risk of subsequent
pulmonary exacerbations [12], which can affect the rate of lung
function decline [13].
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While multiple antibiotic strategies have been studied for
the eradication of P. aeruginosa, many protocols include
inhaled tobramycin as the backbone of the regimen. Random-
ized control trials of inhaled tobramycin have shown both
tobramycin 80 mg twice daily and tobramycin 300 mg twice
daily to be more effective than placebo for eradicating
P. aeruginosa from the airways of children with CF [14,15].
However, there have not been any studies evaluating the
effectiveness of these eradication protocols within the clinical
setting. This is particularly important because not all antimi-
crobial agents are equally available to all patients due to
costs and health insurance coverage, and not all patients fully
comply with the protocol, resulting in varying treatment
durations.
The objectives of this study were thus to compare the
effectiveness of two inhaled tobramycin regimens (inhaled
tobramycin (80 mg/2 ml twice daily, typically for 365 days)
or tobramycin inhalation solution (TIS) (300 mg/5 ml twice
daily, typically for 28 days) with respect to 1) P. aeruginosa
eradication and 2) development of chronic infection. In addition,
we sought to identify risk factors for recurrence of P. aeruginosa
following eradication therapy.
2. Materials and methods
2.1. Subject population and data collection
This was a retrospective observational study based on data
collected from the Toronto Cystic Fibrosis Database as
previously described [16]. Pediatric patients (b18 years of age)
followed at the Hospital for Sick Children Cystic Fibrosis
clinic from 2005–2012 were eligible for this analysis (n = 453).
A detailed description of the inclusion/exclusion criteria is
presented in Fig. 1. We focused on incident P. aeruginosa
cases during the study period, thus patients were excluded if they
had a positive P. aeruginosa culture prior to 2005, if they did not
have a positive P. aeruginosa culture before 2012, or had a lung
transplant. All microbiology data were based on culture results
from sputum, bronchoalveolar lavage samples or throat swabs.
To be included in these analyses, patients had to have at least 3
negative cultures documented in the previous 12 months, have
received inhaled antibiotics within 180 days of the incident
positive P. aeruginosa culture, and had at least one culture after
the end of treatment. Patients with incomplete exposure and
outcome data in the database were excluded from the study. This
study was approved by the Research Ethics Board at the Hospital
for Sick Children (REB# 1000013759).
2.2. Definitions of variables
Height and weight measurements from all clinic visits were
used to calculate body mass index (BMI), which were then
converted to age-standardized z-scores using the WHO 2006
growth charts for children b2 years of age, and the CDC 2000
growth charts for children ≥2 years of age [17,18]. Children
older than 5 years of age routinely performed spirometry at
our clinic. Absolute values of forced expiratory volume in 1 s
(FEV1) were corrected for height, age and sex and analyzed as
percent predicted and z-scores [19]. Thereafter FEV1 was
summarized as 1) FEV1 at the time of first P. aeruginosa
infection and 2) the rate of FEV1 change in the year preceding
the first P. aeruginosa infection, calculated using all available
observations for each patient separately. A pulmonary exacer-
bation was defined as a hospitalization for respiratory
symptoms requiring intravenous antibiotics [20]. Burkholderia
cepacia complex, Haemophilus influenzae, Staphylococcus
aureus and Stenotrophomonas maltophilia infections were
classified as any positive sputum or throat swab culture in the
year preceding first P. aeruginosa infection. MRSA infection
was not included due to its low prevalence in the CF population
in Canada and in this center [21].
2.3. Treatment categorization
Patients were categorized according to treatment received:
inhaled tobramycin (80 mg/2 ml twice daily, typically for
365 days) or tobramycin inhalation solution (TIS) (300 mg/5 ml
twice daily, typically for 28 days). TIS was introduced in
this CF clinic in 2007 and the 1 month TIS regimen was thus
preferentially used from 2007 onwards when medical insurance
was available to cover the costs; prior to 2007, inhaled
tobramycin (80 mg/2 ml) was used. The treatment received was
verified in the patient medical records. Inhaled antibiotics had to
be given within 180 days of the incident P. aeruginosa positive
culture to be considered as treatment associated with the first
positive culture.
2.4. Outcomes
We compared the two tobramycin regimes with respect to
two outcomes 1) P. aeruginosa eradication based on the
microbiological results of the first culture after the patient
stopped treatment and 2) development of chronic infection
defined as N50% of cultures were positive for P. aeruginosa
[22] in the year after the patient stopped initial treatment.
We also investigated risk factors for P. aeruginosa
recurrence, both for 1) time to next P. aeruginosa infection
and 2) P. aeruginosa recurrence in the 12 months following
antimicrobial treatment.
2.5. Statistical analysis
The proportion of eradication failures and the proportion of
patients that developed chronic P. aeruginosa infection (N50%
of cultures positive in the year after treatment ended) were
compared using Fisher's Exact test. The risk factors for time to
subsequent P. aeruginosa after the end of treatment were
assessed using univariable Cox proportional hazard analysis,
whereas the risk factors for becoming P. aeruginosa positive in
the year following the end of treatment were assessed using
univariable logistic regression analysis.
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3. Results
3.1. Study population characteristics
Of the patients who developed incident P. aeruginosa
infection (n = 65, Table 1), the median age of incident
P. aeruginosa was 7.4 years (IQR (3.2; 10.3)), the mean
baseline FEV1% predicted was 89% (SD 16.1) and the mean
BMI was within the normal range (zBMI 0.05, SD(0.8)). The
majority of patients were culture positive for Staphylococcus
aureus and Haemophilus influenzae in the year prior to incident
P. aeruginosa infection; none were infected with B. cepacia
complex and few were infected with S. maltophilia. Baseline
characteristics of the two treatment groups were similar, with
the exception that the TIS group had more respiratory cultures
taken in the year prior to incident P. aeruginosa infection. The
TIS group also had more respiratory cultures taken after the end
of treatment, and was more likely to be cultured sooner after
stopping treatment. Of note, of the 37 patients who received
inhaled tobramycin 80 mg/2 ml, 24 did so before 2007 and 13
received tobramycin 80 mg after 2007.
3.2. Success of eradication
Eradication was evaluated in each treatment regime by
examining the first respiratory tract culture after stopping
treatment (Fig. 2). Of the 28 subjects treated with TIS 300 mg,
3 (11%) were positive for P. aeruginosa on the first culture
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Fig. 1. Selection of study population. (cx: culture, PA: P. aeruginosa)
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following the end of therapy (median treatment time 27 days;
median culture time 21.5 days after end of TIS). In the 37
subjects treated with inhaled tobramycin 80 mg, 4 (11%) were
positive for P. aeruginosa after stopping therapy (median
treatment time 347 days; median culture time 83 days). The
difference in the proportion of patients who achieved successful
eradication of P. aeruginosa following inhalation therapy was
not statistically different between the two groups (p = 0.99). Of
the patients treated with inhaled tobramycin 80 mg, 5 were
culture positive during treatment: 4 became negative by the end
of therapy and 1 remained positive.
3.3. Development of chronic infection
The development of chronic P. aeruginosa infection, as
defined by the Leeds criteria (N50% of cultures positive)
[22], was determined in the 12 months following the end
of treatment in both groups. There was no significant
difference in the proportion of subjects who developed chronic
P. aeruginosa infection in the 12 months following the end of
therapy between the two treatment groups (2 (7.2%) from the
TIS group, 2 (5.4%) from the tobramycin group; p = 0.773). Of
the subjects who were initially P. aeruginosa negative after
stopping treatment, one developed chronic P. aeruginosa
infection in the TIS group, whereas none develop chronic
P. aeruginosa in the group treated with inhaled tobramycin
80 mg (Fig. 2). Of the subjects who were P. aeruginosa
positive after treatment, one patient developed chronic infection
in the TIS group, and two patients in the inhaled tobramycin
80 mg group.
3.4. Risk factors for recurrence of P. aeruginosa infection
A total of nine of 28 (32%) patients treated with TIS had at
least one positive respiratory culture for P. aeruginosa in the
year following treatment, compared to six of 37 (16%) patients
treated with inhaled tobramycin 80 mg; these proportions were
not significantly different (p = 0.150). Table 2 compares
the risk factors for recurrence of P. aeruginosa positive culture
in the 12 months after the end of treatment, irrespective of
treatment. Female patients, older patients, pancreatic insuffi-
cient patients, those with lower lung function and lower body
Table 1




n = 37 (56.9%)
TIS
n = 28 (43.1%)
p value
Median years of observation (IQR) 3.97 (2.0; 8.1) 3.58 (2.1; 8.0) 5.75 (1.9; 8.4) 0.596
Median no. of respiratory cultures/year (IQR) 4.12 (3.3; 4.9) 3.70 (3.1; 4.4) 4.58 (4.0; 6.3) 0.002
Median age at first infection (IQR) 7.43 (3.2; 10.3) 6.47 (2.8; 11.0) 7.67 (3.4; 9.8) 0.801
Female, n (%) 38 (58.5) 21 (56.8) 17 (60.7) 0.614
Genotype, n (%)
Homozygous ΔF508 36 (55.4) 16 (43.2) 20 (71.4)
Heterozygous ΔF508 23 (35.4) 16 (43.2) 7 (25)
Other/Other 5 (7.7) 4 (10.8) 1 (3.6) 0.110
Unknown 1 (1.5) 1 (2.7) 0 (0)
Pancreatic status, n (%)
Insufficient 59 (90.8) 33 (89.2) 26 (92.9) 0.692
Sufficient 6 (9.2) 4 (10.8) 2 (7.1)
CF related diabetes mellitus, n(%) 5 (7.7) 1 (2.7) 4 (14.3) 0.156
Lung function
Baseline FEV1% pred (mean (SD)) 89.2 (14.1) 89.3 (12.3) 89.1 (16.1) 0.818
Change in FEV1% pred (mean (SD)) −0.75 (4.3) −0.95 (4.4) −0.54 (4.2) 0.946
Pulmonary exacerbation, n (%) 2 (3.1) 2 (5.4) 0 0.641
Body mass index (z-score for age)
Baseline zBMI (mean (SD)) 0.05 (0.8) 0.01 (0.8) 0.09 (0.9) 0.525
Change in zBMI (mean (SD)) 0.03 (0.1) 0.03 (0.1) 0.03 (0.2) 0.510
Infection in year prior to first PA infection
B. cepacia complex, n (%) 0 0 0 –
S. aureus, n (%) 49 (75.4) 28 (75.7) 21 (75) 0.950
H. influenzae, n (%) 34 (52.3) 21 (56.8) 13 (46.4) 0.409
S. maltophilia, n (%) 5 (7.7) 1 (2.7) 4 (14.3) 0.156
First PA isolate
Mucoid, n (%) 3 (4.6) 0 3 (10.7) 0.075
Sputum sample, n (%) 38 (58.5) 21 (56.8) 17 (60.7) 0.803
Time since last culture (median days (IQR)) 91 (63; 98) 91 (63;103) 83.5 (52; 91) 0.109
Time to start of treatment (median days (IQR)) 7 (0; 14) 8 (5,17) 4.5 (0; 12) 0.109
Treatment characteristics
Treatment time (median days (IQR)) a 347 (195;370) 27 (27,27) b0.001
Time to first culture off treatment (median days (IQR)) 40 (17; 97) 83 (27; 104) 21.5 (16; 41) 0.005
Median no. of cultures/year after first infection (IQR) 5.8 (4.4; 7.2) 5.2 (4.3; 6.6) 6.4 (5.4; 8.5) 0.023
PA: P. aeruginosa; FEV1: forced expiratory volume in 1 s; IQR: interquartile range.
a See individual treatment regimens.
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mass index were more likely to have a positive culture. A
longer interval between infection and start of treatment also
increased the likelihood of a positive culture, as did the
frequency of respiratory cultures after the end of treatment.
The limited sample size precluded multi-variable analysis of
these risk factors. When the risk factors of age, FEV1 and
BMI were examined using values from the beginning of the
12 months post-eradication treatment and in a time varying
manner, they were not significantly associated with recurrence
of P. aeruginosa infection.
These risk factors for re-infection were similar to risk factors
for initial acquisition. The risk factors for initial infection
were assessed by comparing the study cohort of 65 patients
to children followed in the clinic who did not develop
P. aeruginosa, infection. A total of 96 of the 133 patients
who met the same inclusion/exclusion criteria were used for
this study analysis (i.e. transplant patients excluded, at least one
year of observation etc.). Compared to this sample of patients
that were negative for P. aeruginosa during the same time
period, patients who acquired P. aeruginosa for the first time




Treated with Tobramycin (80 mg/2 ml)
N=37









Treated with TIS (300 mg/5 ml)
N=28


















Fig. 2. Patient outcomes after treatment of incident Pseudomonas aeruginosa infection with inhaled tobramycin.
Table 2
Risk factors for recurrence of P. aeruginosa infection in year following




Female gender 2.39 (1.9; 3.1) b0.001
Older age at first infection 1.1 (1.06; 1.12) b0.001
Pancreatic insufficient 4.61 (3.4; 6.31) b0.001
Lung function
Baseline FEV1% pred at time of first infection 0.90 (0.89; 0.91) b0.001
Change in FEV1% pred in the year prior
to first infection
1.01 (0.97; 1.04) 0.768
Body mass index (z-score for age)
Baseline zBMI at time of first infection 0.72 (0.62; 0.83) b0.001
Change in zBMI in the year prior to first infection 0.14 (0.07; 0.30) b0.001
Culture rate after end of treatment 1.07 (1.05; 1.11) b0.001
Time to start of treatment 1.02 (1.01; 1.02) b0.001
Mucoid status 1.32 (0.77; 2.27) 0.305
Fig. 3. Kaplan–Meier curve for time to subsequent positive P. aeruginosa
infection for entire study population.
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were older (7.4 years vs 4.4 years, p = 0.003), were more likely
to be pancreatic insufficient (90.8% vs 76.0%, p = 0.021),
and were less likely to be infected with S. aureus (75% vs 95%,
p = 0.001).
3.5. Time to subsequent P. aeruginosa infection
Twelve months after the end of treatment, more than 70% of
all patients remained free of P. aeruginosa infection (Fig. 3). Of
those that did reacquire P. aeruginosa, the median time to next
infection was 117 days (IQR 31.5; 143). Pancreatic sufficient
patients were more likely to remain P. aeruginosa free in the
year after the end of treatment (HR 5.30; 95%CI 1.7; 16.7). No
other risk factors emerged using univariable Cox proportional
hazard models.
4. Discussion
To our knowledge, this study is the first to evaluate the
clinical effectiveness of two regimens of inhaled tobramycin
therapy in the eradication of P. aeruginosa from the airways
of young children with CF. It demonstrates that treatment
of CF patients with inhaled tobramycin at a concentration
of 80 mg/2 ml for 1 year or with TIS of 300 mg/5 ml for
1 month appears to have similar effectiveness in achieving
P. aeruginosa eradication with low rates of chronic infection
in both groups. The eradication rates achieved in clinical
practice compare favorably to those seen in previously reported
controlled clinical trials.
Antimicrobial therapy for the eradication of P. aeruginosa has
been used for almost 30 years and has been shown in several
studies to be superior to placebo alone [14,15,23]. Many
regimens include inhaled tobramycin as a major component of
the treatment protocol. Eradication failure rates following
treatment with inhaled tobramycin alone range from 7–21%
[14,24–27] which is consistent with the eradication failure rate of
11% in our study. Studies have less commonly examined the
development of chronic P. aeruginosa infection as an outcome
measure but Proesmans et al. [26] have demonstrated a 5% rate of
chronic infection at 1 year following inhaled tobramycin therapy,
similar to that found in this current study. In addition, as with the
ELITE study comparing 28 to 56 days of TIS, longer duration of
therapy did not result in improved outcomes in this study,
although it has to be noted that tobramycin doses differed
between the two groups [27].
It is notable that the results of the present study, which
occurred in a clinical setting, are comparable to the findings
from those in controlled research studies. Examining the
effectiveness of a therapy in an observational study rather
than its efficacy within a randomized controlled trial, is prone
to treatment selection bias because, in an observational study,
patients are more likely to be treated if they have more severe
disease, often resulting in worse clinical outcomes [28,29]. In
addition, patients in this study were not as closely followed and
monitored as those in a clinical trial [15,25]. Our patients were
also not pre-selected according to stringent inclusion criteria
including the presence of negative P. aeruginosa antibodies.
Serum IgG antibodies to P. aeruginosa are known to rise in CF
patients who develop chronic, mucoid P. aeruginosa infection
and although they are not frequently used in North America
for the diagnosis of P. aeruginosa infection in CF, in many
European CF centers the presence of anti-P. aeruginosa
antibodies is a criteria in the diagnosis of chronic infection
[1,30,31]. Excluding subjects with positive P. aeruginosa
antibodies, representing more established infection, may increase
the success rate of eradication therapy in a study environment that
is not replicated in a clinical setting [14,24,27]. Despite all of
these factors, eradication therapy with as little as 1 month of
inhaled tobramycin was shown to be effective in eradicating
P. aeruginosa infection and preventing the development of
chronic infection in the vast majority of patients in our clinic.
These conclusions are clinically relevant given the additional
treatment burden of 12 months of treatment compared to
1 month of treatment. Although the medical insurance coverage
for each therapy may differ, the overall cost of both regimens is
similar in most countries after taking into account the treatment
duration. Given the apparent comparable effectiveness of these
two eradication strategies, in settings where cost is not a factor,
most patients and clinicians would likely favor the shorter
treatment course (1 month).
Our study was also the first to identify risk factors for
recurrence of P. aeruginosa infection following eradication
therapy. Some of the variables such as older age, pancreatic
insufficiency (as an indicator of CFTR function) and female
gender have been recognized as risk factors for initial
P. aeruginosa infection in CF either in analysis of this current
dataset or in previous studies [9–11]. However, additional,
potentially modifiable risk factors for P. aeruginosa recur-
rence were identified including worse lung function and
nutritional status at the time of first infection and delay in
initiating eradication therapy. As aerosol deposition is less
homogeneous in patients with reduced lung function, this
could suggest that these patients may benefit from additional
systemic therapy, but further evidence is needed to support
this hypothesis. In addition, we demonstrated that patients
with S. aureus infection were less likely to have initial
P. aeruginosa acquisition whereas previous studies identified
it as a risk factor for P. aeruginosa infection, suggesting
that further investigation of the role of the CF pulmonary
microbiome in P. aeruginosa infection is required.
There were several limitations to this study. Compared to
some other clinical trials of P. aeruginosa eradication [32,33],
our sample size was smaller, limiting our ability to adjust for
potential confounding factors. As this was a retrospective
analysis of registry data and an evaluation of the effectiveness of
anti-P. aeruginosa eradication protocols in an actual CF clinic,
there was a considerable variation in the timing of initiation of
therapy. In addition follow up sputum cultures were typically
obtained in the first month following the end of TIS therapy
whereas they were usually obtained 3 months following the end
of inhaled tobramycin (80 mg/2 ml) treatment. This led to an
intrinsic favoring of tobramycin 80 mg in any analysis of time to
next positive P. aeruginosa infection. While we took these
variations into account in the analyses, these differences in the
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treatments and procedures precluded more detailed analysis of
time to subsequent infection. Finally, TIS was introduced at our
center in 2007 resulting in a bias towards more recent incident
P. aeruginosa cases being treated with TIS.
In conclusion, this study demonstrates that inhaled tobramycin
is effective in eradicating P. aeruginosa infection as well as
preventing the development of chronic P. aeruginosa infection in
CF patients in an actual clinic setting. Further work is needed,
however, to be able to accurately identify which patients will
fail initial inhaled tobramycin therapy, and what role the
P. aeruginosa bacterium and the polymicrobial community of
the CF lung play in this failure, in order to develop more effective
antimicrobial rescue treatment strategies.
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